ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ABUS Arbutus Biopharma Corporation

2.84
0.11 (4.03%)
After Hours
Last Updated: 00:30:45
Delayed by 15 minutes
Share Name Share Symbol Market Type
Arbutus Biopharma Corporation NASDAQ:ABUS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.11 4.03% 2.84 2.70 2.79 2.765 2.68 2.74 1,028,210 00:30:45

Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

05/08/2020 1:00pm

GlobeNewswire Inc.


Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Arbutus Biopharma Charts.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 3:30 PM ET.

A live webcast of the presentation can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast.  An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection.  Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier President and CEO Phone: 267-469-0914 Email: ir@arbutusbio.com Pam Murphy Investor Relations Consultant Phone: 267-469-0914 Email: ir@arbutusbio.com

 

1 Year Arbutus Biopharma Chart

1 Year Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart

Your Recent History

Delayed Upgrade Clock